| Fosrenol (lanthanum carbonate) / Takeda |
2013-003949-41: Vascular calcification due to phosphate binders in patients on hemodialysis Vasculaire calcificatie veroorzaakt door fosfaatbinders in patienten aan de hemodialyse. |
|
|
| Ongoing | 4 | 16 | Europe | calciumcarbonate, lanthanum carbonate, Chewable/dispersible tablet, Cachet, calciumcarbonate, lanthanum carbonate | VU medical Center, Vu medical center | Vascular calcification, phosphate binders and patients on hemodialysis Vasculaire calcificatie, fosfaatbinders en patienten die hemodialyse ondergaan, Vascular calcification Vasculaire calcificatie, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2013-002270-52: Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failure evaluar la estabilidad/beneficio del tratamiento con Cinacalcet sobre el tratamiento convencional en base al metabolismo óseo, la rigidez arterial y la calcificación vascular en la insuficiencia renal crónicaavanzada. |
|
|
| Ongoing | 4 | 80 | Europe | Cinacalcet, Rocaltrol, Fosrenol, Cinacalcet, Rocaltrol, Fosrenol | Hospital Universitari de Girona Dr.Josep Trueta, Hospital Universitari de Girona Dr.Josep Trueta | Bone\'s disorders and mineral metabolism and vascular involvement trastornos del metabolismo óseo y mineral y la afectación vascular | | | | |
2016-002602-39: levels of the hormone FGF23 in healthy volunteers with a low phosphate level |
|
|
| Ongoing | 4 | 10 | Europe | Fosrenol, SUB21835, Chewable tablet, lathanum carbonate (Fosrenol) | Radboud University Medical Center, Radboud University Medical Center, innovation funds dutch health insurance companies | healthy volunteers the information of this pilot study will be used in the care of patients with hypophosphatemia due to renal phosphate wasting, conditions leading to increased levels of hormones (ie FGF23) that result in a low phosphate level due to increased renal phosphate loss, Body processes [G] - Physiological processes [G07] | | | | |
2019-003698-24: Feasibility of an approach in which treatment of high phosphate levels with phosphate binders in dialysis patients is based on preferences of the patient. Haalbaarheid van een behandelstrategie gebaseerd op voorkeuren van de patiënt in de behandeling van hoog fosfaat in hemodialysepatiënten |
|
|
| Not yet recruiting | 4 | 40 | Europe | Film-coated tablet, Chewable tablet, Powder for oral suspension, Renvela, Velphoro, Fosrenol | Amsterdam UMC, location VUmc, Dutch Kidney Foundation | Chronic kidney disease, End-stage renal disease Chronische nierziekten, eindstadium nierfalen, Chronic kidney disease Chronische nierziekten, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04485039: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders |
|
|
| Completed | 4 | 44 | US | Tecovirimat, TPOXX, sevelamer carbonate oral tablet, Renvela, sucroferric oxyhydroxide chewable tablet, Velphoro, calcium acetate oral tablet, PhosLo, Lanthanum Carbonate Chewable Tablet, Fosrenol | SIGA Technologies, Biomedical Advanced Research and Development Authority, PPD DEVELOPMENT, LP | Smallpox | 12/22 | 04/23 | | |
LAVALIER, NCT02237534: Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia |
|
|
| Enrolling by invitation | 4 | 60 | Japan | Lanthanum carbonate, FOSRENOL®, Calcium Carbonate | Osaka University, Bayer | Renal Insufficiency, Chronic, Hyperphosphatemia, Bone Diseases, Metabolic | 03/23 | 09/23 | | |
| Recruiting | 3 | 35 | Europe | Lanthanum Carbonate | Universitair Ziekenhuis Brussel | Secondary Hyperoxaluria, Nephrolithiasis | 12/22 | 12/22 | | |
2015-000619-42: An open, phase II, clinical trial to evaluate the effectiveness of decreased intestinal absorption of phosphorus in the progression of renal disease in patients with metabolic syndrome Ensayo clínico fase II, abierto, para evaluar la eficacia de la disminución de la absorción intestinal del fósforo en la progresión de la enfermedad renal en pacientes con síndrome metabólico |
|
|
| Ongoing | 2 | 99 | Europe | Powder for oral solution in sachet, Fosrenol | FIBICO, FIBICO | Chronic kidney disease and metabolic syndrome Enfermedad renal cronica y sindrome metabolico, Chronic kidney disease and metabolic syndrome Enfermedad renal cronica y sindrome metabolico, Not possible to specify | | | | |
NCT06218290: A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis |
|
|
| Completed | 2 | 106 | US | Oxylanthanum Carbonate, OLC | Unicycive Therapeutics, Inc | Chronic Kidney Disease Requiring Chronic Dialysis | 05/24 | 05/24 | | |
NCT04440696: To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder |
|
|
| Recruiting | 1/2 | 48 | RoW | Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo | Grand Life Science (Liaoning) Co., Ltd., The First Hospital of Jilin University | Hyperphosphatemia | 06/22 | 12/22 | | |
ChiCTR-TRC-10000817: Efficacy and safety of lanthanum carbonate for chronic renal failure patients on dialysis with hyperphosphatasemia |
|
|
| Completed | N/A | 240 | | lanthanum carbonate ;lanthanum carbonate placebo | Changzheng Hospital of Shanghai; Fresenius Kabi (China) Co., LTD, Fresenius Kabi (China) Co., LTD | chronic renal failure patients | | | | |
ACTRN12607000046404: Randomised Controlled Trial of Lanthanum carbonate vs Calcium carbonate on Vascular Calcification and Arterial Stiffness in Haemodialysis Patients:
A Pilot Study |
|
|
| Not yet recruiting | N/A | 50 | | | Department of Nephrology, Monash Medical Centre, Clayton, Oprhan Australia (Shire Pharmaceuticals) | Cardiovascular disease and arterial stiffness in end-stage kidney disease | | | | |
ACTRN12613000762752: Mortality among dialysis patients prescribed sevelamer hydrochloride and lanthanum carbonate compared with calcium-based phosphate binders: A retrospective cohort study using the Australian and New Zealand Dialysis and Transplant Database (ANZDATA).
|
|
|
| Active, not recruiting | N/A | 15000 | | | A/Prof Grahame Elder, NA | Chronic Kidney Disease stage 5D (dialysis), All cause mortality and cardiovascular mortality, calcium and non calcium-based phosphate binders | | | | |
